2023 Q3 Form 10-Q Financial Statement

#000095017023042411 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.570M $5.532M
YoY Change 13.95% 27.35%
% of Gross Profit
Research & Development $13.26M $17.06M
YoY Change -7.32% 51.08%
% of Gross Profit
Depreciation & Amortization $140.0K $133.0K
YoY Change 29.63% 44.57%
% of Gross Profit
Operating Expenses $18.82M $22.60M
YoY Change -1.93% 44.48%
Operating Profit -$18.82M -$22.60M
YoY Change -1.93% 44.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.033M $2.659M
YoY Change 103.83% 315.47%
Pretax Income -$15.79M -$19.94M
YoY Change -10.81% 32.92%
Income Tax
% Of Pretax Income
Net Earnings -$15.79M -$19.94M
YoY Change -10.82% 32.92%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28 -$0.36
Diluted Earnings Per Share -$0.28 -$0.36
COMMON SHARES
Basic Shares Outstanding 55.99M 55.95M
Diluted Shares Outstanding 55.99M 55.95M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $290.9M $303.1M
YoY Change -15.48% -15.66%
Cash & Equivalents $27.94M $27.20M
Short-Term Investments $263.0M $275.9M
Other Short-Term Assets $2.400M $2.957M
YoY Change -43.6% 1152.97%
Inventory
Prepaid Expenses $2.395M $1.963M
Receivables
Other Receivables
Total Short-Term Assets $294.5M $306.0M
YoY Change -15.48% -15.39%
LONG-TERM ASSETS
Property, Plant & Equipment $1.778M $1.861M
YoY Change -3.47% 3.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $444.0K
YoY Change -14.16% -6.33%
Total Long-Term Assets $5.326M $5.585M
YoY Change -12.42% -10.06%
TOTAL ASSETS
Total Short-Term Assets $294.5M $306.0M
Total Long-Term Assets $5.326M $5.585M
Total Assets $299.9M $311.6M
YoY Change -15.43% -15.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.207M $1.922M
YoY Change -15.83% -7.19%
Accrued Expenses $10.18M $10.21M
YoY Change 30.72% 92.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.39M $12.13M
YoY Change 19.0% 64.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.500M $2.702M
YoY Change -22.34% -20.08%
Total Long-Term Liabilities $2.500M $2.702M
YoY Change -22.34% -20.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.39M $12.13M
Total Long-Term Liabilities $2.500M $2.702M
Total Liabilities $14.91M $14.84M
YoY Change 9.4% 37.76%
SHAREHOLDERS EQUITY
Retained Earnings -$165.8M -$150.0M
YoY Change 77.52% 98.15%
Common Stock $452.0M $448.8M
YoY Change 3.15% 3.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $285.0M $296.8M
YoY Change
Total Liabilities & Shareholders Equity $299.9M $311.6M
YoY Change -15.43% -15.3%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$15.79M -$19.94M
YoY Change -10.82% 32.92%
Depreciation, Depletion And Amortization $140.0K $133.0K
YoY Change 29.63% 44.57%
Cash From Operating Activities -$14.53M -$13.80M
YoY Change 4.54% 31.47%
INVESTING ACTIVITIES
Capital Expenditures $50.00K $89.00K
YoY Change -116.13% -136.48%
Acquisitions
YoY Change
Other Investing Activities $15.32M $12.07M
YoY Change -124.29% -107.7%
Cash From Investing Activities $15.26M $11.98M
YoY Change -124.07% -107.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 210.0K
YoY Change -93.38% -203.96%
NET CHANGE
Cash From Operating Activities -14.53M -13.80M
Cash From Investing Activities 15.26M 11.98M
Cash From Financing Activities 10.00K 210.0K
Net Change In Cash 740.0K -1.612M
YoY Change -100.96% -99.04%
FREE CASH FLOW
Cash From Operating Activities -$14.53M -$13.80M
Capital Expenditures $50.00K $89.00K
Free Cash Flow -$14.58M -$13.89M
YoY Change 7.29% 35.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001807120
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40288
dei Entity Registrant Name
EntityRegistrantName
Design Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3929248
dei Entity Address Address Line1
EntityAddressAddressLine1
6005 Hidden Valley Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92011
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
293-4900
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
DSGN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55986657
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27197000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26500000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
275891000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
303887000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2957000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4732000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
306045000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
335119000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1861000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1947000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3280000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3612000
CY2023Q2 us-gaap Other Assets
OtherAssets
444000
CY2022Q4 us-gaap Other Assets
OtherAssets
459000
CY2023Q2 us-gaap Assets
Assets
311630000
CY2022Q4 us-gaap Assets
Assets
341137000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1922000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3025000
CY2023Q2 dsgn Accrued Expenses And Other Current Liabilities Related Parties Current
AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
677000
CY2022Q4 dsgn Accrued Expenses And Other Current Liabilities Related Parties Current
AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
640000
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10211000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7751000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12133000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10776000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2702000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3051000
CY2023Q2 us-gaap Liabilities
Liabilities
14835000
CY2022Q4 us-gaap Liabilities
Liabilities
13827000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55986657
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55943314
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55979199
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55895596
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
448784000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
441424000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149995000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110764000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3356000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
296795000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
327310000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
311630000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
341137000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17064000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11295000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32794000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20054000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5532000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4344000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11453000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8955000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
22596000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
15639000
us-gaap Operating Expenses
OperatingExpenses
44247000
us-gaap Operating Expenses
OperatingExpenses
29009000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22596000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15639000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44247000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29009000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2659000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
640000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5016000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
745000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19937000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14999000
us-gaap Net Income Loss
NetIncomeLoss
-39231000
us-gaap Net Income Loss
NetIncomeLoss
-28264000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55948990
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55948990
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55670780
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55670780
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55928625
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55928625
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55589510
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55589510
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19937000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14999000
us-gaap Net Income Loss
NetIncomeLoss
-39231000
us-gaap Net Income Loss
NetIncomeLoss
-28264000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-993000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1356000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2071000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19955000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15992000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37875000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30335000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
312818000
CY2023Q2 dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
7000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
206000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3719000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19937000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
296795000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
327310000
dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
9000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
206000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7145000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1356000
us-gaap Net Income Loss
NetIncomeLoss
-39231000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
296795000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
370309000
CY2022Q2 dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
4000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
225000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2617000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-993000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14999000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
357163000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
382130000
dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
166000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
225000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4977000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2071000
us-gaap Net Income Loss
NetIncomeLoss
-28264000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
357163000
us-gaap Profit Loss
ProfitLoss
-39231000
us-gaap Profit Loss
ProfitLoss
-28264000
us-gaap Depreciation
Depreciation
262000
us-gaap Depreciation
Depreciation
174000
us-gaap Share Based Compensation
ShareBasedCompensation
7145000
us-gaap Share Based Compensation
ShareBasedCompensation
4977000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2539000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
39000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
20000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
35000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
4000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1790000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1020000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1325000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1813000
dsgn Increase Decrease In Accounts Payable And Other Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndOtherLiabilitiesRelatedParties
-7000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31228000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22327000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
95984000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
157976000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
127875000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
1715000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
39000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
176000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
320000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31715000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156542000
dsgn Issue Of Common Stock Through Employee Stock Purchase Plan
IssueOfCommonStockThroughEmployeeStockPurchasePlan
206000
dsgn Issue Of Common Stock Through Employee Stock Purchase Plan
IssueOfCommonStockThroughEmployeeStockPurchasePlan
225000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
156000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
427000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
210000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-46000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
697000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-178915000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298569000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27197000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119654000
dsgn Initial Recognition Of Right Of Use Asset And Operating Lease Liability
InitialRecognitionOfRightOfUseAssetAndOperatingLeaseLiability
590000
dsgn Deferred Financing Costs In Accrued Expenses
DeferredFinancingCostsInAccruedExpenses
75000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
222000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Design Therapeutics, Inc. (the “Company”) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s lead product candidate is in Friedreich ataxia (“FA”), its second product candidate is in Fuchs endothelial corneal dystrophy (“FECD”), and it is also advancing its GeneTAC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">program to address other serious nucleotide repeat-driven monogenic diseases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company completed its initial public offering (“IPO”) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">selling </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,800,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. Proceeds from the Company's IPO, net of underwriting discounts and commissions and other offering costs, were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">254.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses since inception and had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of June 30, 2023. The Company had cash, cash equivalents and investment sec</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">urities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">303.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023, and has not generated positive cash flow from operations.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management expects to incur net losses for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the nonclinical manufacturing, and clinical development activities as well as the commercialization of the Company's products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. The Company's currently available cash and cash equivalents as of June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are sufficient to meet its anticipated cash requirements for more than 12 months following the date the financial statements are issued.</span>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150000000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
303100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8031292
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5410243
CY2023Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
299434000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
324782000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
277891000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2005000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
275891000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
307243000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3369000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
303887000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
113
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
77
CY2023Q2 dsgn Number Of Domestic Certificates Of Deposit Held
NumberOfDomesticCertificatesOfDepositHeld
55
CY2023Q2 dsgn Accrued Interest Receivable On Available For Sale Investment Securities
AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities
1000000
CY2022Q4 dsgn Accrued Interest Receivable On Available For Sale Investment Securities
AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities
1100000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1963000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3617000
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
994000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1115000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2957000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4732000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2645000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2469000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
784000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
522000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1861000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1947000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5396719
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.64
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2414000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3543000
CY2023Q2 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6515000
CY2022Q4 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2983000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
677000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
640000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
605000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
585000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10211000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7751000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
449000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
918000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
945000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
973000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
663000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3948000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
569000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3379000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
500000
us-gaap Operating Lease Cost
OperatingLeaseCost
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2764064
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.76
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7796
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
139914
CY2022Q4 dsgn Unvested Stock Liability
UnvestedStockLiability
9000
dsgn Unvested Stock Liability Vested Shares Value
UnvestedStockLiabilityVestedSharesValue
5000
CY2023Q2 dsgn Unvested Stock Liability
UnvestedStockLiability
4000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.56
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8013073
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.3
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3719000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2617000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7145000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4977000

Files In Submission

Name View Source Status
dsgn-20230630_pre.xml Edgar Link unprocessable
dsgn-20230630_def.xml Edgar Link unprocessable
dsgn-20230630_lab.xml Edgar Link unprocessable
dsgn-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-042411-index-headers.html Edgar Link pending
0000950170-23-042411-index.html Edgar Link pending
0000950170-23-042411.txt Edgar Link pending
0000950170-23-042411-xbrl.zip Edgar Link pending
dsgn-20230630.htm Edgar Link pending
dsgn-20230630.xsd Edgar Link pending
dsgn-ex31_1.htm Edgar Link pending
dsgn-20230630_htm.xml Edgar Link completed
dsgn-ex32_1.htm Edgar Link pending
dsgn-ex99_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img267412975_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending